A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Highly Selective NaV1.8 Inhibitor JKN2306 in Healthy Chinese Subjects
{{output}}
JKN2306 is a novel, highly selective Nav1.8 inhibitor under development for the treatment of acute pain. This first-in-human study aimed to evaluate its safety, tolerability, pharmacokinetics, and food effect (FE). This was a single center, randomized, double-... ...
